5.09%QQQQ 34.86 3.65%XLF 17.80 5.22%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
VALENCIA, Calif. - Biotechnology company MannKind Corp. said Monday its first-quarter loss narrowed on lower research and development costs.
| MNKD | 3.59 |  -0.19 |
The company lost $71.4 million, or 70 cents per share, compared with a loss of $73.1 million, or $1 per share, during the same period a year prior. Revenue rose to $20,000 from $10,000. During the most recent period, MannKind had about 28 million additional shares of common stock outstanding.
Analysts polled by Thomson Financial expected a loss of 79 cents per share, with no revenue.
Research and development expenses fell by 8 percent to $58.4 million, more than offsetting a 15 percent rise to $15.7 million in general and administrative expenses.
Shares rose 4 cents to close at $2.55.
The Obama campaign launched a campaign ad, short documentary and web site attack...
The Philippine unit of American International Group Inc. sought to dispel concerns Monday that the sale of the country's largest insurer would af...
Jurors in the O.J. Simpson trial worked into the night Friday deliberating the f...
|
Professional Website Design For Corporate - Get a Free Quote Today
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
